Zihipp

Zihipp Limited is a biotechnology company based in London, United Kingdom, focused on developing peptide hormones for the treatment of obesity and diabetes. Established in 2012, Zihipp aims to address the growing health crises of these metabolic disorders by creating innovative weight loss therapies. The company is actively developing a pipeline of oxyntomodulin and PYY peptides, which are designed to optimize the potency and extend the half-lives of key satiety hormones. These therapies target individuals across various demographics, including women, adults, and men, with the goal of providing effective treatment options to mitigate weight gain associated with diabetes.